Table 4

Ischaemic cardiovascular AEs

Placebo (n =1544)Salmeterol (n =1542)FP (n =1552)SFC (n =1546)
Patients with ischaemic CV AE, n (%)166 (11)166 (11)167 (11)144 (9)
Rate* of ischaemic CV AE (no of events)68 (224)70 (240)62 (222)54 (199)
Probability† of ischaemic CV AE by 3 years, %14.613.413.811.3
Hazard ratio95% CIp Value
SFC vs placebo0.760.61 to 0.950.016
Salmeterol vs placebo0.930.75 to 1.160.531
FP vs placebo0.930.75 to 1.150.477

  • ↵* Rate=number of events per 1000 treatment years.

  • ↵† Kaplan–Meier probability.

  • AEs, adverse events; CV, cardiovascular; FP, fluticasone propionate; SFC, salmeterol/fluticasone propionate combination.